Digital Control Subjects for Alzheimer's Disease Clinical Trials (AMIA 2019)

Objective: To develop a method to model disease progression that simulates detailed clinical data records for subjects in the control arms of Alzheimer's disease clinical trials.Methods: We used a robust data processing framework to build a machine learning dataset from a database of subjects in the control arms of a diverse set of 28 clinical trials on Alzheimer's disease. From this dataset, we selected 1908 subjects with 18-month trajectories of 44 variables and trained a model capable of simulating disease progression in 3-month intervals across all variables.Results: Based on a statistical analysis comparing data from actual and simulated subjects, the model generates accurate subject-level distributions across variables and through time. Focusing on a common clinical trial endpoint for Alzheimer's disease (ADAS-Cog), we show the model can predict disease progression as accurately as several supervised models. Our model also predicts the outcome of a clinical trial whose data are distinct from the training and test datasets.Conclusion: The ability to simulate dozens of clinical characteristics simultaneously is a powerful tool to model disease progression. Such models have useful applications for clinical trials, from analyzing control groups to supplementing real subject data in control arms.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Blog

AD/PD 2021: Unlearn will present novel, AI-driven approaches to enabling smaller, more efficient Alzheimer’s clinical trials

Press

How Digital Twin Technology is Disrupting Healthcare

Press

Next-gen digital health innovation in clinical trials

The Rock Health team reflects on the evolution of digital in clinical trials, discuss the current state, and explore the opportunity to further transform drug discovery.
The use of digital twins in the healthcare industry is revolutionizing clinical processes.
Join us at The 15th​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, March 9 - 14, 2021.